scholarly journals Metastases from Occult Breast Cancer: A Case Report of Carcinoma of Unknown Primary Syndrome

2020 ◽  
Vol 13 (3) ◽  
pp. 1158-1163
Author(s):  
Erika Barbieri ◽  
Chiara Annunziata Pasqualina Anghelone ◽  
Damiano Gentile ◽  
Carlotta La Raja ◽  
Alberto Bottini ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Primary Breast Tumor ◽  
Unknown Primary ◽  
Breast Cancers ◽  
Cup Syndrome ◽  
Occult Breast Cancer ◽  
Carcinoma Of Unknown Primary ◽  
Patient Reported ◽  
Immunohistochemical Analyses ◽  
Radiological Examinations

Carcinoma of unknown primary (CUP) syndrome occurs when metastases from an unknown primary site spread to multiple organs. Occult breast cancer (OBC) is defined as a clinically recognizable metastatic carcinoma from an undetectable primary breast tumor. It accounts for 0.3–1% of all breast cancers, often presenting with lymph node, bone, and skin metastases. Clinical and radiological examinations represent the first steps in the diagnostic algorithm for CUP syndrome from OBC. However, histological and immunohistochemical analyses, multidisciplinary team evaluation, and a multidisciplinary therapy are essential in the diagnosis and treatment of CUP syndrome from OBC. We report the case of a 52-year-old woman who underwent the removal of a parietal skin lesion. The histological and immunohistochemical analyses suggested a breast cancer origin. Clinical assessment and laboratory and radiological examinations did not locate the primary tumor. Hormone therapy was offered to the patient; however, she refused it. After 28 months, the patient reported a right cervical lump, and a total-body positron emission tomography showed dissemination of the disease to the lymph nodes and bone. A CUP syndrome from OBC was diagnosed. A multimodality approach with radiotherapy and hormone and biological therapy was started. At present, 5 years from the first presentation, the patient is asymptomatic despite the disseminated disease.

scholarly journals Bone and lymph node metastases from occult mammary carcinoma: a case report of carcinoma of unknown primary (CUP) Syndrome

2019 ◽  
Vol 5 (4) ◽  
pp. 20190064
Author(s):  
Antonino Cattafi ◽  
Mariacarmela Santarpia ◽  
Martina Francesca Micalizzi ◽  
Carmelo Sofia ◽  
Elvira Condorelli ◽  
...  
Keyword(s):  
Medical Oncology ◽  
The Body ◽  
Skeletal Structure ◽  
Unknown Primary ◽  
Breast Cancers ◽  
Cup Syndrome ◽  
Carcinoma Of Unknown Primary ◽  
Node Metastases ◽  
Vertebral Bodies ◽  
Oncology Unit

Cancer of unknown provenance is a rare disease, accounting approximately for up to 1% of all breast cancers. A 68-year-old female was admitted to the Medical Oncology Unit of Policlinico Universitario G.Martino because of diffused bone-involvement, with mixed (osteolytic/osteoblastic) features, which interested almost every skeletal structure of the body (vertebral bodies of the entire column, costal skeleton, sternum, proximal third of both humeri, scapulae, clavicles, pelvis and femurs), suspicious for metastatic disease.

scholarly journals Occult Breast Carcinoma Presenting as Scalp Metastasis

2017 ◽  
Vol 10 (3) ◽  
pp. 992-997 ◽  
Author(s):  
Ricardo L.B. Costa ◽  
Rubens B. Costa-Filho ◽  
Marilin Rosa ◽  
Brian J. Czerniecki
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Breast Tumor ◽  
Rare Case ◽  
De Novo ◽  
Metastatic Breast ◽  
Primary Breast Tumor ◽  
Occult Breast Cancer ◽  
Scalp Metastasis ◽  
Occult Breast Carcinoma

Breast cancer is the most common tumor among women, and approximately 6% of the patients have de novo metastatic breast cancer. Occult breast cancer accounts for only 0.1–0.8% of the cases and most commonly presents with axillary lymphadenopathy. Scalp metastases are rare and have been described as a sign of progression or widespread metastatic disease. Here, we describe a rare case of de novo metastatic breast cancer to the scalp as the single site of spread and without an identifiable primary breast tumor.

Gynecologic Cancers: Cervical, Uterine, and Ovarian Cancers

2016 ◽  
pp. 667-672
Author(s):  
Andrea E. Wahner Hendrickson
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Unknown Primary ◽  
Primary Cancer ◽  
Histologic Diagnosis ◽  
Carcinoma Of Unknown Primary ◽  
Ovarian Cancers ◽  
Primary Origin ◽  
Symptoms And Signs ◽  
Unknown Primary Origin

Carcinoma of unknown primary origin (CUP) describes a metastatic disease for which the primary cancer cannot be identified. Of all invasive malignancies, 2% to 6% are CUP. The most common tumor associated with CUP is adenocarcinoma. Squamous cell carcinoma and undifferentiated neoplasms make up a smaller portion of CUP. When a pathologic diagnosis is established, additional evaluation should be tailored according to the patient’s risk factors (eg, smoking and breast cancer risk), symptoms and signs, sites of metastasis, and the histologic diagnosis.

scholarly journals Diffuse Bone Marrow Metastasis as the Initial Presentation of an Occult Breast Cancer

2018 ◽  
Vol 2018 ◽  
pp. 1-8 ◽  
Author(s):  
Frank S. Fan ◽  
Chung-Fan Yang ◽  
Yi-Fen Wang
Keyword(s):  
Breast Cancer ◽  
Bone Marrow ◽  
Interleukin 1 ◽  
Growth Factor Receptor ◽  
Metastatic Potential ◽  
Initial Presentation ◽  
Unknown Primary ◽  
Bone Marrow Metastasis ◽  
Mucin 1 ◽  
Occult Breast Cancer

Introduction. Breast cancer is one of the malignancies which tend to involve the bone marrow, but initial presentation with diffuse bone marrow metastasis from an occult breast cancer is very rare. Prognosis is generally very poor for marrow metastasis from solid tumors except that breast cancer is a treatable disease even in such a dismal condition. Case. A 64-year-old woman’s headache was found to result from diffuse adenocarcinoma metastasis in the bone marrow from an unknown primary site. Intensive immunohistochemistry study of bone marrow biopsy specimen confirmed the disease nature to be an estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast cancer. Mammography and magnetic resonance imaging of breasts revealed a suspicious primary lesion in the right breast. Treatment with tamoxifen alone achieved a sustained response. Discussion. Mucin 1 (MUC1), also known as cancer antigen 15-3 (CA 15-3), facilitates motility and metastatic potential of breast cancer cells. Interleukin-1β (IL-1β) drives breast cancer cell growth and colonization in bone marrow adipose tissue niche. Receptor activator of nuclear factor kappa-B (RANK) and its ligand (RANKL) activate osteoclasts to make a favorable bone marrow microenvironment for tumor cells. Agents against MUC1, IL-1β, and RANKL might be of therapeutic effect for patients like ours.

scholarly journals Response to Vemurafenib in Metastatic Triple-Negative Breast Cancer Harbouring a BRAF V600E Mutation: A Case Report and Electronically Captured Patient-Reported Outcome

2021 ◽  
pp. 616-621
Author(s):  
Magdalena Pircher ◽  
Thomas Winder ◽  
Andreas Trojan
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Treatment Options ◽  
Braf Inhibitor ◽  
Local Therapy ◽  
Braf V600e Mutation ◽  
Braf V600e ◽  
Breast Cancers ◽  
Patient Reported

Effective treatment options are still scarce for metastatic triple-negative breast cancers. An increasing interest in the mutational landscape of this disease will facilitate novel therapeutic strategies in a variety of cancers. Here we report the case of a 38-year-old female patient who developed multiple lung metastasis of a triple-negative breast cancer 2 years after the completion of local therapy. When she progressed after two palliative chemotherapy lines and local electroporation, a next-generation sequencing revealed a BRAF V600E mutation for which we initiated therapy with the BRAF inhibitor vemurafenib. Radiological improvement was already evident after 3 months and has been ongoing for 19 months so far with very few side effects, as is demonstrated by electronically captured patient-reported outcomes. To our knowledge, this is the first published case where a BRAF V600E-mutated advanced triple-negative breast cancer was successfully treated with vemurafenib.

scholarly journals Occult Breast Carcinoma Presenting as Gastrointestinal Metastases

2009 ◽  
Vol 2009 ◽  
pp. 1-3 ◽  
Author(s):  
Lonzetta Neal ◽  
Nicole Sookhan ◽  
Carol Reynolds
Keyword(s):  
Breast Cancer ◽  
Gastrointestinal Tract ◽  
Axillary Lymph ◽  
Breast Cancers ◽  
Axillary Lymph Node Metastases ◽  
Occult Breast Cancer ◽  
Metastatic Lesions ◽  
Occult Breast Carcinoma ◽  
Node Metastases ◽  
Gastrointestinal Metastases

Occult breast cancer has frequently been described as presenting as axillary lymph node metastases but rarely as gastrointestinal metastases, Varadarajan et al. (2007). In extremely rare situations, cancerous lesions identified in the gastrointestinal tract have been determined to be metastatic lesions from primary breast cancers, Taal et al. (2000). We report a case of an occult lobular adenocarcinoma presenting as gastrointestinal metastases. It is essential that the possibility of lesions found in the gastrointestinal tract originating from distant or occult cancers be considered in order that appropriate therapeutic options may be discussed and considered early after diagnosis.

scholarly journals 392 Magseed-Guided Wide Local Excision During the COVID-19 Pandemic: A Tenable Solution to Barriers in Accessing Elective Breast Cancer Surgery

2021 ◽  
Vol 108 (Supplement_6) ◽  
Author(s):  
J J Teh ◽  
W Cai ◽  
M Kedrzycki ◽  
P T R Thiruchelvam ◽  
D S Elson ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Local Excision ◽  
Wide Local Excision ◽  
Ductal Carcinoma ◽  
Patient Flow ◽  
University Hospital ◽  
Breast Cancer Surgery ◽  
Breast Cancers ◽  
Suitable Alternative ◽  
Patient Reported

Abstract Introduction Magseed-guided localisation has emerged as a suitable alternative to wire-guided localisation (WGL) for impalpable breast cancers, with advantages including advanced insertion and simpler logistical planning. Given the severe disruption to elective surgeries during the Covid-19 pandemic, a local Magseed pathway was developed enabling safe patient flow. Magseed was inserted well in advance of the operation, enabling time to self-isolate and obtain a negative COVID swab prior to admission to a dedicated COVID -free suite. We present the patient-reported outcomes of the new pathway. Method A prospective service evaluation was conducted in a University hospital. Patients undergoing Magseed-guided wide local excision (WLE) from 01/07/2020 to present were surveyed to detail their experiences on the Magseed pathway. Qualitative data investigating anxiety and comfort post-insertion were reported using 10-fold Likert scales. Quantitative data was collected on patient demographics and tumour specification. Results 41/46 women who underwent Magseed localisation WLE completed the survey, with median age 65 years (IQR 53-72) and median BMI 26.5 kg/m2 (IQR 22.4-30.8). 71% had invasive ductal carcinoma with or without ductal carcinoma in-situ. 10% women found the procedure uncomfortable (<5) and 98% women reported low anxiety (<5) over seed displacement. If given the choice, 98% patients would prefer Magseed over WGL. Conclusions The new Magseed pathway is regarded positively among patients, despite ongoing disruption in elective breast cancer services. Given the progression of the second wave and likelihood of future outbreaks, Magseed localisation could be adopted widely to ensure continuous provision of safe elective surgeries.

Sign in / Sign up

Export Citation Format

Share Document